Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

zed, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome. The study will include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy. Up to four dose levels may be evaluated in a serial ascending fashion. Once an optimal or maximal dose is identified, additional patients will be added to confirm clinical observations.

"The clinical trial will be conducted at multiple cancer centers in the United States," said Brian P. Zambrowicz, Ph.D., executive vice president and chief scientific officer at Lexicon. "The clinical trial sites will include The University of Texas M.D. Anderson Cancer Center in Houston, Texas; the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida; and Hematology Oncology Services of Little Rock, Arkansas."

LX1032 is being developed in a product development collaboration with Symphony Capital Partners, L.P. and its co-investors.

About LX1032

LX1032 was discovered and developed at Lexicon to reduce serotonin production by inhibiting tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin. Excessive levels of serotonin have been implicated in symptoms associated with carcinoid syndrome. Serotonin's breakdown product, 5-HIAA, is a biomarker used in the diagnosis of the condition. In preclinical studies, LX1032 reduced peripheral serotonin and urinary 5-HIAA levels in several different species without affecting serotonin levels in the brain. In Phase 1 clinical studies, LX1032 reduced serotonin levels and urinary 5-HIAA in healthy volunteers consistent with preclinical results. LX1032 is being developed for the treatment of gastrointestinal symptoms associated with carcinoid syndrome in patients who
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... (PRWEB) May 26, 2015 The ... with the Max Planck Society establishing the ... Photonics. The center will link two of the world's ... will be only the third Max Planck Centre in ... international society for optics and photonics, was with ...
(Date:5/26/2015)... 2015 WORMS, GERMANY – May ... (NYSE: GRA) announces that its manufacturing facility in ... certification from EXCiPACT™, an independent organization that certifies ... , All three Grace facilities that produce ... silica gels have now received GMP certification, following ...
(Date:5/26/2015)... HILDEN, Deutschland, May 26, 2015 ... ®   ermöglicht klinischen Laboren ... dazugehöriger Berichte; Vorstellung auf den Konferenzen ClinGen, ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... QIAGEN Clinical Insight ® (QCI™) bekannt. ...
(Date:5/26/2015)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ) announced today ... provide an update on the progress of Sangamo,s ZFP Therapeutic ... business strategy at 1:30pm ET on Monday, June 1, 2015, ... being held in New York, NY . ... be accessed via a link on the Sangamo BioSciences website ...
Breaking Biology Technology:Third Max Planck Centre in North America Inaugurated at University of Ottawa 2Third Max Planck Centre in North America Inaugurated at University of Ottawa 3CORRECTION: Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 2QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 3QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 4QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 5QIAGEN bringt klinische Bioinformatik-Plattform für Next Generation Sequencing-Anwendungen auf den Markt 6Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2
... BOSTON, Aug. 17, 2011 PAREXEL International Corporation (NASDAQ: ... provider, has been named Company of the Year for ... Awards, the only global, all-encompassing business awards program honoring ... for helping its global client base increase the efficiency ...
... scientists from The University of Nottingham has shown for ... which change the structure of carbon nanotubes can be ... challenges previous scientific thinking that the internal surface of ... use to that of an inert container or a ...
... the world of solar energy, organic photovoltaic solar cells ... are still considered an upstart. While these carbon-based cells, ... are much thinner and less expensive to produce than ... still lag behind in their ability to efficiently convert ...
Cached Biology Technology:PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 2PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 3PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 4PAREXEL Named Company of the Year for the Pharmaceutical Industry in International Business Awards(SM) 5Carbon nanotube structures changed by 'attack' from within, researchers discover 2Nano Gold Rush: Researchers use tiny gold particles to boost organic solar cell efficiency 2
(Date:5/25/2015)... SYDNEY , May 25, 2015  Australia,s market ... inception stage, although 2014 saw the advent of several ... on 24 April 2015 is expected to ignite interest ... devices in Australia . This in ... the industry and drive new partnerships amongst vendors and ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/18/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... should live in the Serengeti" How many grizzly ... few tigers in the world" Conservationist biologists grapple ... species they are trying to protect ?a decision steeped ... new paper appearing in the journal Bioscience, the New ...
... Johns Hopkins have discovered what they believe is the "smoking ... period of blood oxygen loss followed by a sudden restoration ... the Hopkins team found that the sudden oxygen bath triggered ... so toxic it kills the cells. The work was published ...
... slogan “milk does a body good,?radiologists are testing use ... gastrointestinal imaging exams—with excellent results. The researchers reported their ... Society of North America (RSNA). , “We are able ... see with the commonly used contrast agent, VoLumen,?said ...
Cached Biology News:Save the whales? Sure, but how many? 2Cell death following blood 'reflow' injury tracked to natural toxin 2Got inexpensive contrast agent? Milk plays new role in imaging 2
NORMAL DONOR DONKEY SERUM...
... Molecular Probes Fc OxyBURST Green reagent ... Simons of Boston University to permit measurement ... internalization and the subsequent oxidative burst directly ... assay reagent consists of bovine serum albumin ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
MOUSE ANTI RABBIT T LYMPHOCTYES Immunogen: Rabbit Thymocytes...
Biology Products: